In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $2.00. Reni Benjamin has given his Buy ...

CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to ...